
    
      Post-marketing study to evaluate the effect of impaired renal function on the
      pharmacokinetics (PK) of deferiprone and its 3-O-glucuronide metabolite and on the safety of
      FerriproxÂ® in subjects with mild, moderate and severe renal impairment as compared to healthy
      volunteers.
    
  